Unichem Laboratories Share Price Target 2026 Analyst Forecast Bull and Bear Case

Unichem Laboratories (NSE: UNICHEMLAB) is a Pharmaceutical Formulations and APIs company trading at Rs 428.25 with a market capitalisation of Rs 3,053 crore. Analysts have set the Unichem Laboratories share price target at Rs 515 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Unichem Laboratories Share Price Target 2026: Key Takeaways

• Unichem Laboratories share price target 2026: Rs 515 (20% upside from CMP Rs 428.25)
• Bull case: Rs 620 | Bear case: Rs 345
• Ticker: UNICHEMLAB | Sector: Pharmaceutical Formulations and APIs | MCap: Rs 3,053 crore
• 52W range: Rs 278.2 to Rs 657.95 | PE: 18x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Unichem Laboratories Company Overview

Unichem Laboratories (NSE: UNICHEMLAB) is a Mumbai-based pharmaceutical company manufacturing branded formulations across cardiac, anti-diabetic, and anti-infective segments for India, US, and international markets. At CMP Rs 428.25 against a 52 week range of Rs 278.2 to Rs 657.95, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 3,053 crore with trailing PE of 18x. Compared to peers in pharma like Ajanta Pharma and Alembic Pharma, Unichem Laboratories is positioned as a potential re-rating candidate toward the Rs 515 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	UNICHEMLAB
Sector	Pharmaceutical Formulations and APIs
CMP (2026)	Rs 428.25
52 Week High	Rs 657.95
52 Week Low	Rs 278.2
Market Cap	Rs 3,053 crore
Trailing PE	18x
12-Month Analyst Target	Rs 515
Bull Case Target	Rs 620
Bear Case Target	Rs 345

Why Is the Unichem Laboratories Share Price Target Set at Rs 515 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Unichem Laboratories share price target of Rs 515 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 428.25.

Structural Sector Tailwinds in Pharmaceutical Formulations and APIs

The Pharmaceutical Formulations and APIs sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Unichem Laboratories’s position among peers in pharma like Ajanta Pharma and Alembic Pharma creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 620 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Unichem Laboratories’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 515 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Unichem Laboratories’s Pharmaceutical Formulations and APIs operations, improving the probability of achieving the Rs 515 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 18x PE, Unichem Laboratories is positioned as a beneficiary of institutional reallocation toward the Rs 620 bull case over the medium term.

Unichem Laboratories Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Unichem Laboratories Share Price Target

Near-term support for Unichem Laboratories is anchored close to the 52 week low of Rs 278.2. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 428.25.

12-Month Unichem Laboratories Share Price Target 2026

The 12-month Unichem Laboratories share price target 2026 is Rs 515, implying approximately 20 percent upside from CMP Rs 428.25. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Unichem Laboratories Share Price Target: FY27 to FY28

The long term Unichem Laboratories share price target for FY27 to FY28 is Rs 620 in the bull case, requiring full earnings delivery, re-rating among peers in pharma like Ajanta Pharma and Alembic Pharma, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Unichem Laboratories in 2026

Bull Case Unichem Laboratories Share Price Target: Rs 620

The bull case Unichem Laboratories share price target of Rs 620 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and APIs tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 428.25.

Bear Case Unichem Laboratories Share Price Target: Rs 345

The bear case Unichem Laboratories share price target of Rs 345 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 278.2.

Scenario	Target	Key Conditions
Bull Case	Rs 620	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 515	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 345	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Unichem Laboratories 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Unichem Laboratories share price target of Rs 515, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 515 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical Formulations and APIs Peers

Intensifying competition from peers in pharma like Ajanta Pharma and Alembic Pharma could compress Unichem Laboratories’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 515 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Unichem Laboratories

Check the Univest Screener for live data

Before considering any investment based on the Unichem Laboratories share price target of Rs 515, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations and APIs sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Unichem Laboratories (NSE: UNICHEMLAB) with full regulatory protection. Study the competitive landscape among peers in pharma like Ajanta Pharma and Alembic Pharma before executing any position.

Plan your entry using the 52 week low of Rs 278.2 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 515 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Unichem Laboratories’s live share price and receive daily stock recommendations.

FAQs on Unichem Laboratories Share Price Target 2026

What is the Unichem Laboratories share price target for 2026?

Ans. The Unichem Laboratories share price target 2026 is Rs 515, implying approximately 20 percent upside from CMP Rs 428.25. Bull case is Rs 620, bear case is Rs 345.

What was the Unichem Laboratories share price target for 2025?

Ans. The 2025 price objective for Unichem Laboratories was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 515, reflecting FY27 growth potential from CMP Rs 428.25.

Is Unichem Laboratories a good investment at Rs 428.25?

Ans. At Rs 428.25, Unichem Laboratories offers potential upside toward Rs 515 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Unichem Laboratories share price target 2026?

Ans. Key risks to the Unichem Laboratories share price target of Rs 515 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and APIs. Monitoring quarterly results is essential.

What is the 52 week high and low of Unichem Laboratories?

Ans. The 52 week high of Unichem Laboratories is Rs 657.95 and the 52 week low is Rs 278.2. At CMP Rs 428.25, the stock offers potential upside toward the Rs 515 price objective.

What are the main growth catalysts for Unichem Laboratories in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and APIs tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Unichem Laboratories compare to its peers?

Ans. Unichem Laboratories operates in Pharmaceutical Formulations and APIs alongside peers in pharma like Ajanta Pharma and Alembic Pharma. At CMP Rs 428.25 with MCap Rs 3,053 crore, it is a potential re-rating candidate toward the Unichem Laboratories share price target of Rs 515 on FY27 delivery.

What is the Unichem Laboratories share price target for 2027?

Ans. The long-term Unichem Laboratories share price target for FY27 to FY28 is Rs 620 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.